

ASX ANNOUNCEMENT

Results of the Annual General Meeting Held on Thursday 12 November 2015

Sydney Australia, 12 November 2015: In accordance with Listing Rule 3.13.2 and section 251AA of the Corporations Act, we advise details of the resolutions and the proxies received in respect of each resolution on the agenda of this morning's Annual General Meeting.

Remuneration Report

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
18,296,706	7,227,485	225,366	10,807,324

The motion was carried as an ordinary resolution on a poll. The details are:

For	Against	Abstain
30,762,971	6,931,485	354,996

Re-election of Director - Mr Kevin Buchi

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
15,068,673	4,892,707	6,523,601	10,508,824

The motion was carried as an ordinary resolution on a poll. The details are:

For	Against	Abstain
27,196,432	4,892,707	6,523,601

Approval of Prior Issue of Options

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
13,541,428	6,355,074	6,293,479	10,803,824

The motion was carried as an ordinary resolution on a poll. The details are:

For	Against	Abstain
26,145,557	6,044,074	6,423,109

Adoption Of Officers' And Employees' Share Option Plan

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
18,637,844	6,972,312	144,353	10,802,372

The motion was carried as an ordinary resolution on a poll. The details are:

For	Against	Abstain
30,553,777	7,351,322	144,353

Issue Of Options Under Officers' And Employees' Share Option Plan To Mr Peter Francis

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
12,361,326	13,394,038	399,145	10,802,372

The motion was carried as an ordinary resolution on a poll. The details are:

For	Against	Abstain
23,938,718	14,177,953	399,145

Issue Of Options Under Officers' And Employees' Share Option Plan To Dr Peter French

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
12,614,053	13,359,238	18,142	10,802,372

The motion was carried as an ordinary resolution on a poll. The details are:

For	Against	Abstain
24,251,445	14,143,153	18,142

Issue Of Options Under Officers' And Employees' Share Option Plan To Mr Kevin Buchi

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
11,742,826	14,010,997	437,610	10,802,372

The motion was carried as an ordinary resolution on a poll. The details are:

For	Against	Abstain
23,440,323	14,734,807	437,610

Issue Of Options Under Officers' And Employees' Share Option Plan To Dr John Chiplin

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
12,172,168	13,185,074	634,191	10,802,372

The motion was carried as an ordinary resolution on a poll. The details are:

For	Against	Abstain
23,809,560	13,968,989	634,191

Issue Of Options Under Officers' And Employees' Share Option Plan To Mr Iain Ross

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
12,364,068	13,394,038	433,327	10,802,372

The motion was carried as an ordinary resolution on a poll. The details are:

For	Against	Abstain
23,935,096	14,177,953	433,327

Approval of 10% Placement Capacity

The instructions given to validly appointed proxies in respect of the resolution were as follows:

For	Against	Abstain	Proxy's discretion
19,399,913	6,134,724	133,245	11,325,923

The motion was carried as a special resolution on a poll. The details are:

For	Against	Abstain
32,340,513	6,138,982	133,245

For further information regarding Benitec and its activities, please contact the persons below, or visit the Benitec website at www.benitec.com.

<i>Company</i>	<i>Investor relations</i>	<i>United States</i>
Carl Stubbings Chief Business Officer Tel: +61 (2) 9555 6986 Email: cstubbings@benitec.com	Kyahn Williamson Buchan Consulting Tel: +61 (3) 9866 4722 Email: kwilliamson@buchanwe.com.au	Tiberend Strategic Advisors, Inc. Joshua Drumm, Ph.D. (Investors) Tel: +1 212 375 2664 Email: jdrumm@tiberend.com Andrew Mielach (Media) Tel: +1 212 375 2694 Email: amielach@tiberend.com

About Benitec Biopharma Limited:

Benitec Biopharma Limited (ASX: BLT; NASDAQ: BNTC; NASDAQ: BNTCW) is a clinical-stage biotechnology company developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi or 'expressed RNAi'. Based in Sydney, Australia with labs in Hayward, CA (USA) and collaborators and licensees around the world, the company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, wet age-related macular degeneration and OPMD. Benitec has also licensed ddRNAi to other biopharmaceutical companies for applications including HIV/AIDS, Huntington's Disease, chronic neuropathic pain and retinitis pigmentosa.